Humata Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $25M (Blue Venture Fund, Optum Ventures, Highmark Ventures). 225+ hospitals. ML recommends which clinical documents to include in prior auth submissions, reducing denials before submission.
About
Humata Health is a prior authorization AI platform serving the provider side of healthcare — helping hospital systems optimize their prior authorization submissions to reduce denial rates before claims are ever sent to payers. The company has raised $25 million from Blue Venture Fund, Optum Ventures, and Highmark Ventures, and is deployed at 225+ hospitals. Founded by an MD, the platform applies ML to recommend the specific clinical documentation that each payer's prior authorization algorithm weights most heavily.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.